In conclusion, LCDs appear to modestly reduce CRP levels overall, with greater effects observed in trials lasting more than 12.5 weeks and among individuals with obesity and elevated baseline CRP concentrations (> 4.5 mg/L). Here, CRP is linked to obesity due to melanocortin 4 receptor deficiency.